Bioheng is rebranding to Imviva Biotech to better reflect our global positioning and expansion.

Bioheng Therapeutics is a clinical-stage company focused on allogeneic "off-the-shelf" universal CAR-T therapies. Founded in 2017, we aim to develop the world’s leading allogeneic cell therapy platforms and products to address some of the most challenging unmet needs.

In February 2025, our CD7-targeted UCAR-T, CTD402, received Investigational New Drug (IND) approval from the U.S. FDA for the treatment of T-ALL/LBL.This product is based on Bioheng's novel and proprietary UCAR-T technology platform - ANSWER®. We are progressing the global clinical trial for this promising pipeline.

Built upon our ANSWER® platform, we are actively developing multiple UCAR-T pipelines. These programs have demonstrated robust and extended allogeneic CAR-T persistence, showing strong potential in both oncology and autoimmune indications.

We are always striving to meet these unmet needs.

Imviva Biotech

Org chart

Teams

Offices